Separately, HC Wainwright lowered Kazia Therapeutics from a buy rating to a neutral rating in a research note on Tuesday.
Kazia Therapeutics Trading Up 4.8 %
KZIA stock opened at $1.86 on Tuesday. The business’s fifty day simple moving average is $4.29 and its two-hundred day simple moving average is $5.95. Kazia Therapeutics has a twelve month low of $1.63 and a twelve month high of $12.28.
Hedge Funds Weigh In On Kazia Therapeutics
About Kazia Therapeutics
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.
- Get a free copy of the StockNews.com research report on Kazia Therapeutics (KZIA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.